Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Reports First Revenues in Q3

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported quarterly revenues for the first time driven by receipts from Parkway Clinical Laboratories, which Rosetta acquired for $2.9 million this past summer.
The Rehovot, Israel-based developer of microRNA-based tests and therapeutics reported revenues of $705,000 for the three-month period ended Sept. 30. All of the revenues came from Parkway, which Rosetta purchased to help expedite development and validation of its first microRNA-based diagnostic tests.
Rosetta is gearing up to launch its first microRNA-based tests for cancer. It is developing tests for differentiating squamous versus non-squamous non-small cell lung cancer, for differentiating between mesothelioma and adenocarcinoma, and for cancer of unknown primary.
The firm’s net loss for the quarter was $3 million, or $.25 per share, compared to a net loss of $2.2 million, or $.18 per share, for the third quarter of 2007.
Rosetta’s R&D costs increased 43 percent to $2 million from $1.4 million year over year. Its marketing, business development, general, and administrative spending rose 25 percent to $1.5 million from $1.2 million.
Rosetta finished the quarter with around $10 million in cash and cash equivalents.
Following the end of the third quarter, Rosetta announced that it had secured $1.5 million in funding from undisclosed private investors to fund a new microRNA-based plant biotechnology project.
It also said that as part of a settlement with the Attorney General of the State of New York and the North American Securities Administrators Association Task Force, investment banking firm Credit Suisse agreed to repurchase $7.4 million worth of auction rate securities held by Rosetta. The firm previously took a $7.4 million impairment charge related to the securities, which experienced multiple failed auctions due to a lack of liquidity in the markets for ARS.
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.